SAMHD1 is a barrier to antimetabolite-based cancer therapies

The outcome of acute myelogenous leukemia (AML) therapy depends on the propensity of leukemic blasts to accumulate ara-CTP, the active triphosphate of cytarabine (ara-C). We identified sterile α motif and HD domain-containing protein 1 (SAMHD1) as an ara-CTPase that protects cancer cells from cytara...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudd, Sean G., Schaller, Torsten, Herold, Nikolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383367/
https://www.ncbi.nlm.nih.gov/pubmed/28401188
http://dx.doi.org/10.1080/23723556.2017.1287554
_version_ 1782520272844226560
author Rudd, Sean G.
Schaller, Torsten
Herold, Nikolas
author_facet Rudd, Sean G.
Schaller, Torsten
Herold, Nikolas
author_sort Rudd, Sean G.
collection PubMed
description The outcome of acute myelogenous leukemia (AML) therapy depends on the propensity of leukemic blasts to accumulate ara-CTP, the active triphosphate of cytarabine (ara-C). We identified sterile α motif and HD domain-containing protein 1 (SAMHD1) as an ara-CTPase that protects cancer cells from cytarabine-induced toxicity. Therefore, we propose targeting SAMHD1 as a strategy to potentiate cytarabine and possibly other antimetabolite-based therapies.
format Online
Article
Text
id pubmed-5383367
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-53833672018-02-03 SAMHD1 is a barrier to antimetabolite-based cancer therapies Rudd, Sean G. Schaller, Torsten Herold, Nikolas Mol Cell Oncol Author's View The outcome of acute myelogenous leukemia (AML) therapy depends on the propensity of leukemic blasts to accumulate ara-CTP, the active triphosphate of cytarabine (ara-C). We identified sterile α motif and HD domain-containing protein 1 (SAMHD1) as an ara-CTPase that protects cancer cells from cytarabine-induced toxicity. Therefore, we propose targeting SAMHD1 as a strategy to potentiate cytarabine and possibly other antimetabolite-based therapies. Taylor & Francis 2017-02-03 /pmc/articles/PMC5383367/ /pubmed/28401188 http://dx.doi.org/10.1080/23723556.2017.1287554 Text en © 2017 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author's View
Rudd, Sean G.
Schaller, Torsten
Herold, Nikolas
SAMHD1 is a barrier to antimetabolite-based cancer therapies
title SAMHD1 is a barrier to antimetabolite-based cancer therapies
title_full SAMHD1 is a barrier to antimetabolite-based cancer therapies
title_fullStr SAMHD1 is a barrier to antimetabolite-based cancer therapies
title_full_unstemmed SAMHD1 is a barrier to antimetabolite-based cancer therapies
title_short SAMHD1 is a barrier to antimetabolite-based cancer therapies
title_sort samhd1 is a barrier to antimetabolite-based cancer therapies
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383367/
https://www.ncbi.nlm.nih.gov/pubmed/28401188
http://dx.doi.org/10.1080/23723556.2017.1287554
work_keys_str_mv AT ruddseang samhd1isabarriertoantimetabolitebasedcancertherapies
AT schallertorsten samhd1isabarriertoantimetabolitebasedcancertherapies
AT heroldnikolas samhd1isabarriertoantimetabolitebasedcancertherapies

Ejemplares similares